Trial reportDiabetologia2024
Discordance between mean glucose and time in range in relation to HbA
Trial report in Diabetologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Patterns of One-Year Change in HbA1c and Continuous Glucose Monitoring (CGM) Metrics in Older Adults with Type 2 Diabetes.Clinical chemistry · 2026Article
- Narrowing the A1c gap: Personalized modeling of HbA1c- continuous glucose monitor discordance in type 1 diabetes.PLOS digital health · 2026Article
- Development and standardisation of 'time-in-range' measurement for clinical endpoints in retinal diseases.Eye (London, England) · 2026Review
- Impact of continuous glucose monitoring on glycaemic risk index in adults with type 1 diabetes using multiple daily insulin injections in the GOLD trial.Frontiers in clinical diabetes and healthcare · 2026Article
- The GMI/HbA1c ratio does not independently predict diabetic retinopathy in adults with Type 1 Diabetes.Scientific reports · 2025Observational
- Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor.Journal of clinical & translational endocrinology · 2025Article
- Glycated hemoglobin is not enough: The role of glycemia risk index for glycemic control assessment in type 1 diabetes.World journal of diabetes · 2025Article
- Managing discordance between HbADiabetic medicine : a journal of the British Diabetic Association · 2025Review
- Association between the GMI/HbA1c ratio and preclinical carotid atherosclerosis in type 1 diabetes: impact of the fast-glycator phenotype across age groups.Cardiovascular diabetology · 2025Article
- Limitations in Achieving Glycemic Targets From CGM Data and Persistence of Severe Hypoglycemia in Adults With Type 1 Diabetes Regardless of Insulin Delivery Method.Diabetes care · 2025Article
- Association Between the Hemoglobin Glycation Index (HGI) and Risk of Diabetic Nephropathy: A Retrospective Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aims/hypothesisPrevious studies have shown that individuals with similar mean glucose levels (MG) or percentage of time in range (TIR) may have different HbA
methodsData from the randomised clinical GOLD trial (n=144) and the follow-up SILVER trial (n=98) of adults with type 1 diabetes followed for 2.5 years were analysed. A total of 596 paired HbA
resultsIn the GOLD trial, the mean age of the participants (± SD) was 44±13 years, 63 (44%) were female, and the mean HbA CONCLUSIONS/
interpretationInter-individual variations exist between MG and HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.